Biomarkers /
RET
Overview
The RET gene (ret proto-oncogene), encodes the proto-oncogene tyrosine-protein kinase receptor Ret, a receptor tyrosine kinase (RTK). Activating point mutations in RET can give rise to the hereditary cancer syndrome, multiple endocrine neoplasia 2 (MEN2; PMID: 11061555). Activating somatic point mutations in RET are associated with sporadic medullary thyroid cancer (PMID: 16946010; PMID: 11061555). Oncogenic kinase fusions involving the RET gene are found in non-small cell lung cancers (PMID: 22395697).
RET is altered in 2.61% of all cancers with lung adenocarcinoma, colon adenocarcinoma, thyroid gland medullary carcinoma, cutaneous melanoma, and melanoma having the greatest prevalence of alterations [3].
The most common alterations in RET are RET Mutation (2.05%), RET Fusion (0.36%), RET Loss (0.33%), RET Codon 918 Missense (0.11%), and RET M918T (0.11%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of RET in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.